RegenMedTX, which acquired the assets of bankrupt organ regeneration technology company Tengion (NSDQ:TNGN) in March, said it raised more than $4 million from a syndicate of 27 unnamed investors. Winston-Salem, N.C.-based RegenMedTX is led by former Tengion CSO Tim Bertram and CTO Deepak Jain, the Winston-Salem Journal reported. Tengion, which pulled the plug in December 2014 after seeking but […]
New inversion rules are unlikely to scuttle Medtronic’s pending $43B merger with Covidien | The week in medtech M&A
New inversion rules unlikely to scuttle Medtronic's $43B Covidien buy
September 24, 2014 by Brad Perriello
Tengion is on the auction block
Tengion’s Q2 losses widen
Tengion raises $74M for organ programs
Tengion (NSDQ:TNGN) said it raised $74.3 million from 22 unnamed investors as it puts a pair of clinical programs through their paces.
The Winston-Salem, N.C.-based medical device company is developing the Neo-Kidney Augment and Neo-Urinary Conduit, human organs that are grown using a bioabsorbable scaffold and patients’ own cells.
Tengion soars on raising $34M in support of organ regeneration platform
Tengion issues updates on clinical trial following patient deaths
Diabetes: Medtronic’s Resolute stent performs well in non-diabetics, too | Wall Street Beat
Abbott wins FDA nod for next-gen cataract laser | Regulatory Roundup
Bovie swings to 2011 black | Earnings Roundup
White House defends Obamacare insurance mandate in Supreme Court brief | MassDevice.com On Call
MASSDEVICE ON CALL — In a Supreme Court briefing on Friday, the Obama administration defended its health care reform law, arguing that the Supreme Court would need to break with clear precedent in order to justify cutting down the insurance mandate.
The health care law requires most all Americans to purchase health insurance or pay a penalty, which the Justice Department defines as an unconstitutional tax. GOP lawmakers are urging the Supreme Court to strike down the entire Affordable Care Act if the individual mandate is deemed unconstitutional.